Virax Biolabs (VRAX) Prepaid Assets (2025 - 2026)
Virax Biolabs (VRAX) posted quarterly Prepaid Assets of $362577.0 for Q1 2026, down 32.78% year-over-year from $539382.0 in Q1 2025, and down 32.78% quarter-over-quarter from $539382.0 in Q1 2025.
Virax Biolabs (VRAX) Prepaid Assets (2025 - 2026) Analysis & Trends
Virax Biolabs' Prepaid Assets history runs 2 years deep, the most recent figure standing at $362577.0 for Q1 2026.
- In Q1 2026, Prepaid Assets fell 32.78% year-over-year to $362577.0; the TTM figure through Mar 2026 stood at $362577.0 (down 32.78% YoY), while the FY2026 annual figure was $362577.0, down 32.78% from the prior year.
- Prepaid Assets for Q1 2026 stood at $362577.0, down from $539382.0 in the prior quarter.
- The five-year high for Prepaid Assets was $539382.0 in Q1 2025, with the low at $362577.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 362,577.00 |
| Mar 31, 2025 | 539,382.00 |